Africa - Arab countries - Asia - Asia-Pacific - Australia - Australia, New Zealand - Austria - Brazil - Bulgaria - Canada - Canada, Europe - Canada, United States - Central and Eastern Europe - China - China, United States - Denmark - Egypt - Europe - Europe, United States - Finland - France - Germany - Ghana - Greece - High-income countries - Hong Kong - India - Indonesia - International - Iran - Ireland - Ireland, Netherlands - Italy - Italy, Spain - Japan - Latin America - Latin America and the Caribbean - Lebanon - Lithuania - Low and middle income countries - Morocco - Netherlands - Netherlands, United Kingdom - New Zealand - Nigeria - Norway - Philippines - Poland - Republic of Korea - Serbia - Singapore - South Africa - Spain - Sub-Saharan Africa - Sweden - Switzerland - Taiwan - Thailand - Türkiye - United Kingdom - United States - Uruguay - Vietnam - Western countries - {Related topics}

Africa

• JCO Global Oncology
  • Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review [2023]

Arab countries

• Health and Quality of Life Outcomes
  • Quality of life in Arab women with breast cancer: a review of the literature [2016]

Asia

• BMJ Open
  • Health-related quality of life in Asian patients with breast cancer: a systematic review [2018]

• Journal of Breast Cancer
  • Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide [2016]

• Systematic Reviews
  • Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis [2024]

Asia-Pacific

• Drug Safety
  • Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel [2023]

Australia

• Asia-Pacific Journal of Clinical Oncology
  • Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia [2026]

• Australian Journal of General Practice
  • Update on the management of early-stage breast cancer [2019]
  • Advanced breast cancer [2019]

• Australian Prescriber
  • Trastuzumab deruxtecan for breast cancer [2022]

• Breast Cancer Trials
  • Breast Cancer Treatment in Australia

• Cancer Australia
  • Guidance for the management of early breast cancer: Recommendations and practice points [2020]

• PLoS ONE
  • Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice [2014]

• Royal Australian College of General Practitioners
  • Bone loss associated with aromatase inhibitor therapy for breast cancer and androgen deprivation therapy for prostate cancer

Australia, New Zealand

• Royal Australian and New Zealand College of Obstetricians and Gynaecologists
  • Tamoxifen and the endometrium [2019]

Austria

• Oncologist
  • Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer [2012]

• Wiener klinische Wochenschrift
  • Updated Austrian treatment algorithm in HER2+ metastatic breast cancer [2022]
  • Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update [2022]

Brazil

• Breast Cancer : Targets and Therapy
  • Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective [2012]

• Current Oncology
  • Treatment Disparities, Heterogeneities, and Barriers to Access for Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A National Survey from Brazil [2025]

• Epidemiologia e Serviços de Saúde
  • Frequency and factors associated with delay in breast cancer treatment in Brazil, according to data from the Oncology Panel, 2019-2020 [2023]

• International Journal of Environmental Research and Public Health
  • Waiting Time between Breast Cancer Diagnosis and Treatment in Brazilian Women: An Analysis of Cases from 1998 to 2012 [2020]

• Lancet Global Health
  • Racial disparities in breast cancer survival after treatment initiation in Brazil: a nationwide cohort study [2024]

• Scientific Reports
  • Incidence of palliative treatment among breast cancer patients undergoing neoadjuvant therapy: an analysis of the Brazilian public health system [2025]

Bulgaria

• Frontiers in Public Health
  • Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria [2023]

Canada

• Alberta Health Services
  • Systemic Therapy for Early Breast Cancer - Quick Reference Guide
  • Follow-up Care for Early-Stage Breast Cancer

• BC Cancer Agency
  • Ixabepilone [2014]

• Breast Cancer Research and Treatment
  • A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles [2022]
  • Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey [2021]

• Canada's Drug Agency
  • Trastuzumab deruxtecan (Enhertu) [2023]
  • Pertuzumab (Perjeta) [2022]
  • Regional Chemotherapy for the Treatment of Breast Cancer: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines [2018]

• Canadian Family Physician
  • Breast Cancer Survivorship Tool [2020]
  • Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians [2016]

• Canadian Journal of Physiology and Pharmacology
  • Preventing broken hearts in women with breast cancer: a concise review on chemotherapy-mediated cardiotoxicity [2024]

• Cancers
  • Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience [2021]

• Current Oncology
  • Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update) [2026]
  • Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada [2025]
  • Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting [2024]
  • An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management [2024]
  • Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective [2023]
  • Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion [2023]
  • Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape [2023]
  • Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain [2022]
  • Systemic treatment approaches in her2-negative advanced breast cancer—guidance on the guidelines [2015]
  • Optimal systemic therapy for early breast cancer in women: a clinical practice guideline [2015]
  • Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [2013]
  • Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada [2013]

• Journal of Bone Oncology
  • Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting [2015]

• Ontario Health
  • Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Cancer Care Ontario’s Position Statement on Guidelines for Breast Cancer Well Follow-Up Care [2012]
  • Tamoxifen
  • Paclitaxel
  • Letrozole
  • Gemcitabine
  • Fulvestrant
  • Exemestane
  • Docetaxel
  • Capecitabine
  • Anastrozole

Canada, Europe

• Breast Cancer
  • Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy [2024]

Canada, United States

• American Society of Clinical Oncology
  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update [2022]
  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline [2017]

• CA: A Cancer Journal for Clinicians
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment [2017]

Central and Eastern Europe

• Pathology & Oncology Research
  • Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [2022]
  • Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [2022]

China

• Annals of Translational Medicine
  • Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study [2021]

• Breast
  • Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study [2023]

• Cancer Biology & Medicine
  • Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification [2022]

• Cancer Chemotherapy and Pharmacology
  • Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer [2020]

• Cancer Innovation
  • Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients [2024]

• Cancer Medicine
  • Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study [2021]

• Chinese Medical Journal
  • Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022 [2024]
  • Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021 [2021]

• Clinical Breast Cancer
  • Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China [2024]

• Frontiers in Oncology
  • Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China [2021]

• Frontiers in Public Health
  • The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012) [2023]

• Journal of Cachexia, Sarcopenia and Muscle
  • Cost-Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China [2025]

• Journal of Evidence-Based Medicine
  • Using Integrative Therapies to Improve Patient-Reported Outcomes in Breast Cancer Survivors: A Living Evidence-Based Clinical Practice Guideline [2025]

• Journal of Oncology
  • Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China [2021]

• OncoTargets and Therapy
  • Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective [2016]
  • Lapatinib for the treatment of breast cancer in the People’s Republic of China [2014]

• PLoS ONE
  • Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review [2023]

• Scientific Reports
  • Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China [2025]

• Supportive Care in Cancer
  • Financial toxicity in female patients with breast cancer: a national cross-sectional study in China [2022]

• Translational Breast Cancer Research
  • A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view [2022]

China, United States

• Breast
  • Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer [2026]

• JAMA Network Open
  • Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021 [2023]

Denmark

• Acta Oncologica
  • Survival outcomes for HER2-low breast cancer: Danish national data [2024]
  • Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer - a nationwide, retrospective study [2024]

• Breast Cancer Research and Treatment
  • A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial [2025]

• Journal of the National Cancer Institute
  • The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis [2022]

Egypt

• Journal of the Egyptian National Cancer Institute
  • Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus [2022]

Europe

• Annals of Oncology
  • Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel [2016]

• BMC Cancer
  • Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe [2015]

• BMC Health Services Research
  • Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries [2020]

• Breast
  • Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective [2017]

• Clinical Breast Cancer
  • A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer [2017]

• Critical Reviews in Oncology/Hematology
  • Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies [2022]

• ESMO Open
  • Flexible care in breast cancer [2021]

• European Medicines Agency
  • Xeloda
  • Tyverb
  • Tukysa
  • Taxotere
  • Perjeta
  • Nerlynx
  • Herceptin
  • Faslodex
  • Enhertu
  • Abraxane

• European Menopause and Andropause Society
  • Osteoporosis management in patients with breast cancer: EMAS position statement [2017]

• European Society for Medical Oncology
  • Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies [2020]

• European Society of Breast Cancer Specialists
  • EUSOMA quality indicators for non-metastatic breast cancer: An update [2024]
  • European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care [2023]

• Journal of Cancer Research and Clinical Oncology
  • Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors [2023]

Europe, United States

• Cancer Treatment Reviews
  • Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality [2022]

• Cancers
  • FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis [2020]

• Clinical Breast Cancer
  • Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer [2021]

• Current Oncology
  • Association of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Scores with Guideline Recommendations in Breast Cancer [2026]

Finland

• European Journal of Health Economics
  • Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland [2024]

• Pharmacoepidemiology and Drug Safety
  • Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study [2026]

France

• BMC Medicine
  • Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women [2023]

• Breast Cancer Research and Treatment
  • Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database [2024]

• ESMO Open
  • Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort [2024]

• European Journal of Cancer
  • Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort [2026]

• Haute Autorité de Santé
  • PHESGO (pertuzumab, trastuzumab) [2021]
  • NERLYNX [2020]

• International Journal of Cancer
  • Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group [2026]

• JAMA Network Open
  • Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France [2022]

Germany

• BMC Cancer
  • The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients [2015]
  • Trastuzumab in advanced breast cancer - a decade of experience in Germany [2014]

• Breast Cancer
  • Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study [2018]

• Breast Care
  • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts [2020]
  • Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) [2019]
  • ABC4 Consensus: Assessment by a German Group of Experts [2018]
  • ABC3 Consensus: Assessment by a German Group of Experts [2016]
  • 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus – Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts [2015]
  • Guideline Conformity Treatment in Young Women with Early-Onset Breast Cancer in Germany [2014]
  • Breast Cancer and Osteoporosis – Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer [2014]
  • 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus – Opinion of a German Team of Experts (Zurich 2013) [2013]
  • Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007 [2011]

• Deutsche Gesellschaft für Radioonkologie
  • Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? [2021]

• Geburtshilfe und Frauenheilkunde
  • Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference [2021]
  • AGO Algorithms for the Treatment of Breast Cancer: Update 2021 [2021]
  • Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report [2020]
  • ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results [2020]
  • Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer [2018]
  • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts [2018]
  • Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus [2017]
  • ABC3 Consensus Commented from the Perspective of the German Guidelines [2016]
  • Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015) [2015]

• Institute for Quality and Efficiency in Health Care
  • Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V [2017]

• International Journal of Cancer
  • A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany [2026]
  • Time trends of neoadjuvant chemotherapy for early breast cancer [2020]

• Journal of Cancer Research and Clinical Oncology
  • The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study [2025]
  • Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a questionnaire-based cross-sectional study using clinical and cancer registry data in Germany [2023]

• Oncology Research and Treatment
  • Treatment Navigation in Breast Cancer Management: Process Cost Analysis Based on German Case Studies [2026]

Ghana

• PLoS ONE
  • Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in Ghana: A nationwide survey [2023]

Greece

• BMC Cancer
  • Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study) [2025]

• BMC Health Services Research
  • Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study [2015]

High-income countries

• Aging
  • Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies [2021]

• Cancer Reports
  • Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis [2023]

• JMIR Cancer
  • Use of AI to Predict and Support Medication Adherence in Patients With Breast Cancer: Systematic Review [2026]

• Journal of Breast Cancer
  • Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis [2022]

• Lancet
  • Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy [2025]

Hong Kong

• Hong Kong Medical Journal
  • Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer Registry [2023]
  • Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong [2023]

India

• Indian Journal of Medical Research
  • Consensus on contentious issues relevant for breast cancer management for the Indian scenario: Statements following a multicentre expert group meeting [2021]
  • Breast cancer survivorship in India [2021]

• Indian Journal of Surgery
  • Indian Solutions for Indian Problems—Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India [2017]

• JCO Global Oncology
  • Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India [2024]
  • Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India [2020]

• South Asian Journal of Cancer
  • Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India [2021]

Indonesia

• PLoS ONE
  • Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis [2024]

International

• Annals of Oncology
  • Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer [2025]
  • Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 [2023]
  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [2021]
  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [2015]

• Annals of Surgical Oncology
  • St. Gallen International Breast Cancer Consensus-Based Clinical Decision Validation: Concordance Assessment Between Deep Large Language Model Outputs and Global Expert Panel Recommendations [2026]

• Asian Pacific Journal of Cancer Prevention
  • Pertuzumab and Pathological Complete Response in Early HER2+ Breast Cancer: A Systematic Review and Meta-analysis of Real-World Studies [2026]

• Biomedicines
  • Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer [2022]

• BMJ Open
  • Evidence-based recommendations on care for breast cancer survivors for primary care providers: a review of evidence-based breast cancer guidelines [2017]

• Breast
  • The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis [2025]
  • Reducing stigma, isolation, and misconceptions in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 8) [2025]
  • Meeting the informational needs of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 6) [2025]
  • Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7) [2025]
  • Improving the quality of life of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (goal 3) [2025]
  • Improving survival outcomes of people with ABC: a global expert review and call-to-action for 2025-2035 (Goal 1) [2025]
  • Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9) [2025]
  • Improving communication between healthcare professionals and patients living with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 5) [2025]
  • Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 4) [2025]
  • Collecting high-quality data for advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 2) [2025]
  • Clinical and economic research of bone modifiers as adjuvant therapy for early breast cancer: A systematic literature review [2025]
  • Advancing the legal rights of people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 10) [2025]
  • Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review [2024]
  • 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) [2024]
  • The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review [2022]
  • Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review [2022]
  • Customizing early breast cancer therapies - The 2021 St. Gallen International Breast Cancer Consensus Conference [2022]
  • Anthracyclines in the treatment of early breast cancer friend or foe? [2022]
  • Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review [2020]

• Breast Cancer Research and Treatment
  • Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials [2025]

• Breast Care
  • St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer [2021]
  • St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [2019]

• Breast Health Global Initiative
  • Breast cancer treatment: A phased approach to implementation [2020]

• British Journal of Cancer
  • Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations [2025]

• Cancer Genomics & Proteomics
  • Pharmacogenetics of Toxicities Related to Endocrine Treatment in Breast Cancer: A Systematic Review and Meta-analysis [2024]

• Cancer Medicine
  • Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis [2023]
  • Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review [2019]

• Cancer Treatment Reviews
  • Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes [2024]
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge [2021]

• Clinical and Translational Science
  • Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis [2022]

• Clinical Breast Cancer
  • Prognostic Value of Immune-Inflammation Indexes for Breast Cancer Patients Undergoing Endocrine Therapy: A Systematic Review and Meta-analysis [2025]

• Clinical Pharmacology & Therapeutics
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy [2018]

• Cochrane Database of Systematic Reviews
  • Psychological interventions for women with non-metastatic breast cancer [2023]
  • Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer [2022]
  • Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer [2021]
  • Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer [2020]
  • Taxanes for adjuvant treatment of early breast cancer [2019]
  • Fulvestrant for hormone-sensitive metastatic breast cancer [2017]
  • Bisphosphonates and other bone agents for breast cancer [2017]

• Critical Reviews in Oncology/Hematology
  • Trastuzumab deruxtecan in breast cancer [2024]
  • Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis [2023]

• Cureus
  • A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles [2024]

• Current Breast Cancer Reports
  • Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer [2017]

• Current Oncology
  • Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis [2023]

• ESMO Open
  • Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis [2022]

• European Society for Medical Oncology
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [2020]
  • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [2018]
  • 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [2017]

• Experimental and Therapeutic Medicine
  • Tyrosine kinase inhibitors in breast cancer (Review) [2022]

• Expert Review of Pharmacoeconomics & Outcomes Research
  • Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review [2024]
  • Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment [2021]

• Frontiers in Oncology
  • Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials [2022]
  • Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs [2019]

• Frontiers in Pharmacology
  • Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis [2023]
  • Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer [2022]

• Geburtshilfe und Frauenheilkunde
  • Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel [2021]

• Health Expectations
  • Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review [2020]

• International Journal of Environmental Research and Public Health
  • Applications of Artificial Intelligence (AI) in Breast Cancer Care Delivery and Education: A Scoping Review [2026]

• International Journal of Molecular Sciences
  • Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review [2025]
  • Epothilones as Natural Compounds for Novel Anticancer Drugs Development [2023]

• JAMA Network Open
  • Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis [2025]

• JCO Clinical Cancer Informatics
  • Mapping the Evidence on the Impact of mHealth Interventions on Patient-Reported Outcomes in Patients With Breast Cancer: A Systematic Review [2024]

• JCO Global Oncology
  • Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact [2021]

• Journal of Bone Oncology
  • Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG [2017]

• Journal of Cancer
  • Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients [2019]

• Journal of Cancer Survivorship
  • Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines [2022]

• Journal of Comparative Effectiveness Research
  • A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib [2024]

• Journal of Managed Care & Specialty Pharmacy
  • Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis [2025]

• Journal of the National Cancer Institute
  • Taxanes for the treatment of breast cancer during pregnancy: an international cohort study [2024]

• Molecular and Clinical Oncology
  • Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment [2019]

• Molecular Medicine
  • Neratinib for HER2-positive breast cancer with an overlooked option [2020]

• npj Breast Cancer
  • Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic [2020]

• Oncologist
  • Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel [2022]

• Oncotarget
  • Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer [2018]

• Patient
  • Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review [2024]

• Plants
  • Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy [2021]

• PLoS ONE
  • The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis [2022]
  • The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis [2021]
  • Global treatment costs of breast cancer by stage: A systematic review [2018]

• Revista Peruana de Medicina Experimental y Salud Pu´blica
  • Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis [2024]

• Supportive Care in Cancer
  • MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw [2024]

• Systematic Reviews
  • Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review [2024]

• Targeted Oncology
  • A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer [2025]

• Therapeutic Advances in Medical Oncology
  • The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis [2019]

Iran

• BMC Health Services Research
  • Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience [2025]

• PharmacoEconomics
  • Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy [2018]

Ireland

• Ireland's Health Services
  • Breast SACT Regimens

Ireland, Netherlands

• PLoS ONE
  • Treatment Strategies and Survival of Older Breast Cancer Patients – An International Comparison between the Netherlands and Ireland [2015]

Italy

• BMC Cancer
  • An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project [2018]

• Breast
  • Influence of adherence with guideline-driven recommendations on survival in women operated for breast cancer: Real-life evidence from Italy [2020]

• Cancer Treatment Reviews
  • Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project [2024]

• Critical Reviews in Oncology/Hematology
  • The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report [2025]

• ESMO Open
  • Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients [2023]

• Future Oncology
  • Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations [2025]

• Oncologist
  • Cardiovascular risk after adjuvant trastuzumab in early breast cancer: an Italian population-based cohort study [2020]

• Tumori
  • The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives [2025]

Italy, Spain

• Breast
  • "Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" [2024]

Japan

• Breast
  • Chemotherapy is associated with differential survival outcomes in apocrine carcinoma: A nationwide cohort study from the Japanese National Clinical Database-Breast Cancer Registry [2026]

• Breast Cancer
  • Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines [2024]
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment [2024]
  • Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community [2024]
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition [2023]
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition [2020]
  • Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer [2013]

• Breast Cancer Research and Treatment
  • A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study [2019]

• Molecular and Clinical Oncology
  • Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan [2015]

Latin America

• JCO Global Oncology
  • Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines [2024]

Latin America and the Caribbean

• Oncologist
  • Health-Related Quality of Life in Patients with Breast Cancer in Latin America and the Caribbean: A Systematic Review and Meta-Analysis [2021]

Lebanon

• BMC Cancer
  • Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients [2015]

Lithuania

• Medicina
  • Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: A consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians [2014]

Low and middle income countries

• BMC Cancer
  • Essential medicines for breast cancer in low and middle income countries [2015]

• Breast Health Global Initiative
  • Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]
  • Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]

Morocco

• Breast Journal
  • Management of breast cancer during COVID-19 pandemic in Morocco [2020]

Netherlands

• Acta Oncologica
  • Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study [2025]

• BMC Cancer
  • Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands [2016]

• Breast
  • Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines [2026]
  • Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival [2022]

• Breast Cancer Research and Treatment
  • Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis [2026]
  • Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry [2024]
  • The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients [2021]
  • The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands [2021]
  • Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry [2021]

• British Journal of Cancer
  • Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer [2018]

• European Journal of Cancer
  • Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial [2025]

Netherlands, United Kingdom

• European Journal of Cancer
  • Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies [2022]

New Zealand

• Breast
  • New Zealand experience with implementation of the ESO-ESMO consensus guidelines for advanced breast cancer-report of achievements and lessons learned [2022]

• Breast Cancer Foundation NZ
  • 2nd New Zealand Consensus Guidelines for Advanced Breast Cancer (ABC-NZ2) [2022]

• International Journal of Environmental Research and Public Health
  • Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival [2020]

• PLoS Medicine
  • Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis [2016]

Nigeria

• ecancermedicalscience
  • Assessment of guideline adherence in breast cancer management among oncologists in Nigeria [2021]

• JAMA Network Open
  • Health Care Professional Adherence to Breast Cancer Management Guidelines in Nigeria [2025]

Norway

• Breast Cancer Research and Treatment
  • Stage-specific survival has improved for young breast cancer patients since 2000: but not equally [2020]

Philippines

• BMC Health Services Research
  • Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines [2019]

Poland

• Contemporary Oncology
  • Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer [2013]

Republic of Korea

• BMC Cancer
  • Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea [2025]

• Breast
  • Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis [2026]
  • Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15) [2025]

• Cancer Research and Treatment
  • Quality Assessment and Trend for Breast Cancer Treatment Practice across South Korea Based on Nationwide Analysis of Korean Health Insurance Data during 2013-2017 [2023]

• ClinicoEconomics and Outcomes Research
  • Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea [2016]

• Frontiers in Oncology
  • Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study [2020]

• Journal of Breast Cancer
  • Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013 [2015]
  • Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference [2014]

• Journal of Korean Medical Science
  • Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data [2018]

• Journal of the American Heart Association
  • Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea [2022]

• Medicina
  • Osteoporosis Associated with Breast Cancer Treatments Based on Types of Hormonal Therapy: A Cross-Sectional Study Using Korean National Sample Data [2023]

• Nutrients
  • Adherence to Guidelines for Cancer Survivors and Health-Related Quality of Life among Korean Breast Cancer Survivors [2015]

• Osteoporosis International
  • Differential fracture risk in breast cancer patients based on endocrine therapy and age: a nationwide cohort study [2025]

• Scientific Reports
  • Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study [2025]

• Women’s Health Nursing
  • Rebuilding life after breast cancer treatment among Korean breast cancer survivors: an integrative review [2026]

Serbia

• JBUON
  • Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE [2018]

Singapore

• Annals Academy of Medicine Singapore
  • Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting [2015]
  • Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer [2015]

• JCO Clinical Cancer Informatics
  • Augmenting Large Language Models With National Comprehensive Cancer Network Guidelines for Improved and Standardized Adjuvant Therapy Recommendations in Postoperative Breast Cancer Cases [2025]

• Scientific Reports
  • Impact of deviation from guideline recommended treatment on breast cancer survival in Asia [2020]

South Africa

• Breast Cancer Research and Treatment
  • The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa [2023]

Spain

• BMJ Quality & Safety
  • Socioeconomic inequalities in adherence to clinical practice guidelines and breast cancer survival: a multicentre population-based study in Spain [2025]

• Breast Cancer Research and Treatment
  • Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort [2022]

• Clinical and Translational Oncology
  • Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management [2024]
  • Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey [2024]
  • Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention [2017]
  • Defining the optimal sequence for the systemic treatment of metastatic breast cancer [2016]

• Health and Quality of Life Outcomes
  • Health-related quality of life in Spanish breast cancer patients: a systematic review [2011]

• Journal of Drug Assessment
  • Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists [2019]

• Oncologist
  • GEICAM Guidelines for the Management of Patients with Breast Cancer During Spain's COVID-19 Pandemic [2020]

• Scientific Reports
  • Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study [2021]

• Sociedad Española de Oncología Médica
  • SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025) [2026]
  • SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) [2026]
  • Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective [2025]
  • SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) [2023]
  • SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) [2023]
  • Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer [2022]
  • SEOM clinical guidelines in early stage breast cancer (2018) [2019]
  • SEOM clinical guidelines in advanced and recurrent breast cancer (2018) [2019]
  • Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC) [2018]
  • SEOM clinical guidelines in metastatic breast cancer 2015 [2015]

Sub-Saharan Africa

• BMJ Open
  • Adherence to Choosing Wisely Africa recommendations in breast cancer care: a cross-sectional study across three Sub-Saharan African centres [2025]

• Breast Cancer Research
  • Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study [2019]

• JAMA Network Open
  • Survival Patterns Among Patients With Breast Cancer in Sub-Saharan Africa: A Systematic Review and Meta-Analysis [2024]

• Lancet Oncology
  • Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study [2022]

Sweden

• Acta Oncologica
  • Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences [2024]

• BMC Cancer
  • Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study [2026]

• Breast
  • Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy [2023]

Switzerland

• Cancers
  • Management and Outcome of Young Women (<=40 Years) with Breast Cancer in Switzerland [2022]

Taiwan

• Breast
  • Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan [2021]

• Cancer Medicine
  • Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study [2023]

• Journal of Cancer
  • Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study [2021]

• PLoS ONE
  • Is tamoxifen good enough for the Asian population in ER+ HER2- post-menopausal women with early breast cancer? A nationwide population-based cohort study [2024]

• Scientific Reports
  • Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan [2022]
  • Health Services Utilisation in Breast Cancer Survivors in Taiwan [2014]

Thailand

• Value in Health Regional Issues
  • Economic Evaluation and Budget Impact of Biosimilar Trastuzumab for HER2-Positive Metastatic Breast Cancer in Thailand: Policy Implications for Access and Affordability [2026]

Türkiye

• Turkish Journal of Surgery
  • Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak [2020]

United Kingdom

• BMJ Open
  • Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer [2021]

• Breast
  • Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET) [2024]

• British Journal of Cancer
  • Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England [2023]
  • A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program [2023]
  • Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study [2021]

• Cancer Biology & Medicine
  • The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK [2015]

• European Journal of Cancer
  • Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data [2024]

• Health Technology Assessment
  • Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT [2020]

• Indian Journal of Surgery
  • Breast Cancer Management Guidelines During COVID-19 Pandemic [2020]

• National Institute for Health and Care Excellence
  • Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) [2025]
  • Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence [2025]
  • Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [2025]
  • Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [2025]
  • Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [2024]
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [2023]
  • Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [2022]
  • Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2022]
  • Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer [2022]
  • Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence [2022]
  • Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [2021]
  • Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [2020]
  • Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [2019]
  • Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [2019]
  • Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2019]
  • Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer [2018]
  • Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer [2018]
  • Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [2018]
  • Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane [2017]
  • Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [2016]
  • Everolimus with exemestane for treating advanced breast cancer after endocrine therapy [2016]
  • Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [2016]
  • Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab [2013]
  • Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 [2012]
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer [2012]
  • Fulvestrant for the treatment of locally advanced or metastatic breast cancer [2011]
  • Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer [2011]
  • Gemcitabine for the treatment of metastatic breast cancer [2007]

• PharmacoEconomics - Open
  • Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [2023]

• UK Parliament
  • Treatment of lobular breast cancer [2024]

United States

• American Cancer Society
  • American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline [2015]

• American College of Medical Genetics and Genomics
  • Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy [2012]

• American College of Obstetricians and Gynecologists
  • Aromatase Inhibitors in Gynecologic Practice [2018]
  • Tamoxifen and Uterine Cancer [2014]

• American College of Radiology
  • Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer
  • Locally Advanced Breast Cancer

• American Family Physician
  • Breast Cancer Treatment [2021]

• American Journal of Managed Care
  • Integrating Trastuzumab Biosimilars and HER2-Directed Therapies into HER2-Positive Breast Cancer Management [2020]

• American Society of Breast Surgeons
  • Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries [2021]

• American Society of Clinical Oncology
  • Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A [2024]
  • Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline [2024]
  • Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update [2024]
  • Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update [2024]
  • Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update [2023]
  • Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update [2023]
  • Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2023]
  • Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update Q and A [2022]
  • Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update [2022]
  • Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A [2022]
  • Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update [2022]
  • Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update [2022]
  • Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2022]
  • Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update [2022]
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline [2021]
  • Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update [2021]
  • Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update [2021]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update [2020]
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline [2019]
  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update [2018]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update [2018]
  • Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline [2018]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update [2017]
  • Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline [2016]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [2016]
  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update [2013]

• Annals of Surgical Oncology
  • The Metaplastic Conundrum: A National Cancer Database Analysis of Metaplastic versus Triple-Negative Ductal Breast Cancer [2025]
  • Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis [2025]

• ASCO Educational Book
  • Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy [2023]
  • What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care [2020]

• BMC Cancer
  • Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data [2025]

• Breast
  • Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists [2025]
  • Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes [2022]

• Breast Cancer : Basic and Clinical Research
  • Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database [2020]

• Breast Cancer : Targets and Therapy
  • Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis [2021]

• Breast Cancer Research and Treatment
  • Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer [2026]
  • Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database [2025]
  • National trends and survival outcomes associated with non-guideline-concordant treatment of inflammatory breast cancer [2025]
  • Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer [2024]
  • Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis [2024]
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium [2020]
  • Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) [2018]
  • Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) [2018]
  • Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines [2013]

• Cancer Control
  • Socioeconomic Status and Breast Cancer Treatment in the United States: Results From a Systematic Literature Review [2025]

• Cancer Management and Research
  • Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer [2009]

• Cancer Medicine
  • Impact of Travel Burden on Timeliness of Care and Overall Survival for Breast Cancer: A National Cancer Database Analysis [2025]
  • Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score >=26: A National Cancer Database analysis [2024]
  • Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey [2015]

• Cancer Treatment Reviews
  • Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan [2024]

• Cancers
  • Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer [2022]

• Clinical Cardiology
  • Are Aromatase Inhibitors Associated with Higher Myocardial Infarction Risk in Breast Cancer Patients? A Medicare Population-Based Study [2018]

• Current Breast Cancer Reports
  • Lessons Learned: Management of Breast Cancer Patients throughout the COVID-19 Pandemic [2021]

• Current Oncology
  • Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations [2025]

• Drug Design, Development and Therapy
  • Management of advanced breast cancer with the epothilone B analog, ixabepilone [2009]

• Expert Review of Anticancer Therapy
  • Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens [2022]

• Food and Drug Administration
  • U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review [2022]
  • FDA approves neratinib for metastatic HER2-positive breast cancer [2020]
  • FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer [2015]

• Frontiers in Oncology
  • Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer [2021]

• International Journal of Clinical Oncology
  • Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases [2025]

• JAMA Network Open
  • Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ [2026]
  • Trends in Guideline-Concordant Care for Inflammatory Breast Cancer [2025]
  • Racial Disparities in Receipt of Guideline-Concordant Care in Older Adults With Early Breast Cancer [2024]
  • Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer [2020]

• JAMA Oncology
  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States [2017]

• JCO Oncology Practice
  • Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach [2020]

• JNCCN
  • Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials [2022]
  • Initiation of Trastuzumab by Women Younger Than 64 Years for Adjuvant Treatment of Stage I-III Breast Cancer [2018]

• Journal of Cancer
  • Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer [2014]

• Journal of Cancer Survivorship
  • Current practice patterns and gaps in guideline-concordant breast cancer survivorship care [2023]

• Journal of Clinical Oncology
  • Late Breast Cancer Survivorship: Side Effects and Care Recommendations [2022]
  • Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter [2016]
  • Decline in the Use of Anthracyclines for Breast Cancer [2012]

• Journal of Managed Care & Specialty Pharmacy
  • First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population [2025]
  • Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective [2025]
  • Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer [2024]

• Journal of Medical Economics
  • Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective [2026]
  • Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study [2025]
  • Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective [2025]
  • Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective [2025]

• Journal of the Advanced Practitioner in Oncology
  • Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer [2018]

• National Cancer Institute
  • Drugs Approved for Breast Cancer
  • Childhood Breast Cancer Treatment (PDQ®)
  • Breast Cancer Treatment (PDQ®)

• National Comprehensive Cancer Network
  • Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology [2026]
  • NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 [2025]
  • NCCN resource-stratified and harmonized guidelines: A paradigm for optimizing global cancer care [2020]

• npj Breast Cancer
  • HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now [2021]
  • Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond [2020]

• Signal Transduction and Targeted Therapy
  • Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management [2023]

• Society for Immunotherapy of Cancer
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer [2021]

• Society for Integrative Oncology
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment [2017]

• StatPearls
  • Trastuzumab
  • Tamoxifen

Uruguay

• Medicine
  • Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay [2022]

Vietnam

• PLoS ONE
  • Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+ in Vietnam [2024]

Western countries

• Breast
  • Improving medication adherence to endocrine therapy in breast cancer patients: a mixed-methods systematic review of effective communication strategies for healthcare providers [2025]

• ESMO Open
  • Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer [2022]

• Maturitas
  • The effects of lifestyle and behavioural interventions on cancer recurrence, overall survival and quality of life in breast cancer survivors: A systematic review and network meta-analysis [2024]

{Related topics}

• Topic
  • Osteoporosis: risk factors
  • Breast cancer treatment: surgery, radiotherapy
  • Breast cancer